Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-137-6 | CAS number: 103-71-9
Health surveillance data
Administrative data
- Endpoint:
- health surveillance data
- Type of information:
- other: review
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: literature survey
Data source
Reference
- Reference Type:
- publication
- Title:
- Isocyanat-bedingte Gesundheitsgefahren - eine aktuelle Literaturuebersicht
- Author:
- Baur X, Latza U, Barbinova L, Yu F
- Year:
- 2 003
- Bibliographic source:
- Arbeitsmed.Sozialmed.Umweltmed. 38, 270-277
Materials and methods
- Study type:
- other: literature survey
- Endpoint addressed:
- not applicable
- Principles of method if other than guideline:
- In this review clinical findings after exposure to isocyanates were were described.
- GLP compliance:
- no
Test material
- Reference substance name:
- Phenyl isocyanate
- EC Number:
- 203-137-6
- EC Name:
- Phenyl isocyanate
- Cas Number:
- 103-71-9
- Molecular formula:
- C7H5NO
- IUPAC Name:
- isocyanatobenzene
- Reference substance name:
- isocyanates
- IUPAC Name:
- isocyanates
Constituent 1
Constituent 2
Results and discussion
- Results:
- exposure limits: 0.05 mg/m³, 0.01 ml/m³ (ppm) phenylisocyanate
Any other information on results incl. tables
Clinical effects of workers exposed to isocyanates:
Asthma bronchial asthma 62%, no obstructive bronchitis 17%, rhinitis 17%, chronic obstructive bronchitis 11%, conjunctivitis 11%, urticaria/erythema 3%, eczema 2%, fever 2%, exogeneous allergic alveolitis 2%
The main hazardous effects are obstuctive airway diseases.
Applicant's summary and conclusion
- Executive summary:
In this review clinical findings after exposure to isocyanates were were described. In workers exposed to isocyanates the following diagnosis were made:
Asthma bronchial asthma 62%, no obstructive bronchitis 17%, rhinitis 17%, chronic obstructive bronchitis 11%, conjunctivitis 11%, urticaria/erythema 3%, eczema 2%, fever 2%, exogeneous allergic alveolitis 2%
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
